AMI Asset Management Corp decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS – Get Rating) by 0.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 237,639 shares of the company's stock after selling 2,155 shares during the period. Zoetis comprises approximately 2.6% of AMI Asset Management Corp's holdings, making the stock its 18th largest position. AMI Asset Management Corp owned about 0.05% of Zoetis worth $40,848,000 as of its most recent SEC filing.
A number of other hedge funds have also recently modified their holdings of ZTS. American National Bank lifted its stake in shares of Zoetis by 469.2% during the 2nd quarter. American National Bank now owns 148 shares of the company's stock valued at $25,000 after buying an additional 122 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its stake in shares of Zoetis by 430.8% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company's stock valued at $26,000 after buying an additional 112 shares in the last quarter. Worth Asset Management LLC purchased a new stake in Zoetis in the 1st quarter worth $26,000. Financial Management Professionals Inc. lifted its stake in Zoetis by 117.4% in the 1st quarter. Financial Management Professionals Inc. now owns 150 shares of the company's stock worth $28,000 after purchasing an additional 81 shares in the last quarter. Finally, Hanson & Doremus Investment Management lifted its stake in Zoetis by 713.6% in the 1st quarter. Hanson & Doremus Investment Management now owns 179 shares of the company's stock worth $34,000 after purchasing an additional 157 shares in the last quarter. Institutional investors own 91.05% of the company's stock.
Get
Zoetis alerts:
Zoetis Price Performance
Shares of Zoetis stock traded up $0.81 during trading hours on Friday, reaching $151.76. The company's stock had a trading volume of 23,611 shares, compared to its average volume of 1,847,356. The firm has a 50 day moving average price of $165.02 and a 200-day moving average price of $172.29. Zoetis Inc. has a one year low of $147.77 and a one year high of $249.27. The company has a debt-to-equity ratio of 1.14, a current ratio of 2.18 and a quick ratio of 1.46. The stock has a market cap of $71.04 billion, a P/E ratio of 34.08, a P/E/G ratio of 2.66 and a beta of 0.77.
Zoetis (NYSE:ZTS – Get Rating) last posted its earnings results on Thursday, August 4th. The company reported $1.20 earnings per share for the quarter, missing analysts' consensus estimates of $1.22 by ($0.02). The business had revenue of $2.10 billion during the quarter, compared to the consensus estimate of $2.03 billion. Zoetis had a return on equity of 49.03% and a net
margin of 26.14%. The business's quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the firm earned $1.19 earnings per share. On average, analysts predict that Zoetis Inc. will post 5.01 EPS for the current year.
Analyst Ratings Changes
Several analysts have commented on ZTS shares. The Goldman Sachs Group decreased their price target on shares of Zoetis from $208.00 to $202.00 and set a "buy" rating on the stock in a research note on Thursday, July 21st. Piper Sandler started coverage on shares of Zoetis in a research note on Monday, July 11th. They issued an "overweight" rating and a $205.00 price target on the stock. Stifel Nicolaus decreased their price target on shares of Zoetis from $275.00 to $225.00 and set a "buy" rating on the stock in a research note on Friday, June 24th. StockNews.com cut shares of Zoetis from a "strong-buy" rating to a "buy" rating in a research note on Thursday. Finally, William Blair restated an "outperform" rating on shares of Zoetis in a report on Friday, August 5th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $224.00.
Insider Activity at Zoetis
In related news, CEO Kristin C. Peck sold 311 shares of the company's stock in a transaction dated Thursday, July 7th. The shares were sold at an average price of $180.00, for a total transaction of $55,980.00. Following the transaction, the chief executive officer now directly owns 39,743 shares in the company, valued at approximately $7,153,740. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Kristin C. Peck sold 311 shares of the company's stock in a transaction dated Thursday, July 7th. The shares were sold at an average price of $180.00, for a total transaction of $55,980.00. Following the transaction, the chief executive officer now directly owns 39,743 shares in the company, valued at approximately $7,153,740. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kristin C. Peck sold 9,689 shares of the company's stock in a transaction dated Thursday, July 21st. The shares were sold at an average price of $180.00, for a total transaction of $1,744,020.00. Following the transaction, the chief executive officer now owns 39,743 shares in the company, valued at $7,153,740. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 12,167 shares of company stock worth $2,190,623. Insiders own 0.12% of the company's stock.
Zoetis Profile
(Get Rating)
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Further Reading
- Get a free copy of the StockNews.com research report on Zoetis (ZTS)
- This Is A Memorable Time To Buy Into Micron Technology
- Declining Profits Challenge the CarMax Value Proposition
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
- Thor Industries Hammers Out A Bottom
- Let Paychex Stock Work Hard For You
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Get Rating).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
